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Sinecatechins
was theﬁrst botanical drug approved by the Food andDrug Administra-
tion for the treatment of external anogenital warts (U.S. Food and Drug
Administration and Center for Drug Evaluation andResearch, 2006). It is
a formulation of a variety of catechins, a type of polyphenol with potent
antioxidant activity. It has been identiﬁed for its immunostimulatory,
antitumor, and antiproliferative properties (Stockﬂeth et al., 2008).
Although Veregen® has an established role in complete clearance of
anogenital warts; it has not been used for the treatment of VIN. We re-
port a case of a woman with multifocal Usual-type VIN, warty type
disease who was treated with Sinecatechins 15% ointment.Case ReportIntroduction
Vulvar intraepithelial neoplasia (VIN) is a dysplastic premalignant
condition that affects the vulvar squamous epithelium. It is classiﬁed
into usual and differentiated types. If left untreated, VIN may progress
to invasive cancer within 1–7 years (Jones et al., 2005). Although rare,
VIN has become an increasingly common problem in younger women
b50 years of age with a reported 392% increase in incidence from
1994–1997 (Joura et al., 2000). Interestingly, it is not rare to diagnose
invasive cancer at the time of surgery for VIN, with a reported incidence
of up to 5% (ACOG, 2011). A similar trend has been observed in vulvar
cancer patients with a striking increase in incidence noted in the 40–
49 years age group (Joura et al., 2000). High risk human papillomavirus
(HPV) infection, human immunodeﬁciency virus infection, smoking, and
other pelvic neoplasia are some of the documented risk factors for devel-
opment of VIN (ACOG, 2011). Recognized treatment modalities include
partial superﬁcial skinning vulvectomy, wide local excision, CO2 laser
ablation, topical ointments (Imiquimod 5%), and 5-aminolevulinic acid-
based photodynamic therapy (Hillemanns et al., 2006).epartment of Obstetrics and
, USA. Fax: +1 773 257 6359.
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after stem cell transplant (CD4 count 143 cell/mcL), presented her pri-
mary care physician complaining of pruritic lesions on her vulva. She
had no other pertinent risk factors. Physical exam revealed erythema-
tous papules, plaques and ulcerated lesions on the vulva. An ofﬁce biop-
sy was obtained which showed high grade VIN and squamous cell
carcinoma in situ (CIS). The patientwas then referred to the gynecologic
oncology service at our institution for furtherworkup andmanagement.
She was noted to have extensive multifocal and multicentric disease
(Fig. 1). After performing further biopsies in the operating room, all
biopsy specimens were then reviewed by our gynecologic pathologists
and diagnosed as Usual-type VIN, warty subtype, with HPV changes
and CIS. Initially, our recommendations included wide local excision
of the lesions. However, due to its multifocal involvement and need
for excision of the clitoris with extensive reconstruction, more conser-
vative alternatives were considered. We prescribed topical Imiquimod
5% ointment, twice weekly. Patient was followed every two weeks in
clinic and after 8 weeks of treatment, she failed to show any clinical re-
sponse. In addition, due to extreme pain with application, patient was
unable to tolerate the full course, despite use of narcotics and pudendal
block.
Consequently, we prescribed Veregen® ointment, to be used three
times a day for six weeks. Four weeks after start of therapy, visible
improvement in the vulvar lesions was noted. The patient reported
some pain and discomfort at the application sites, but stayed motivat-
ed to complete the treatment, as her lesions appeared to be resolving.
At the end of 6 weeks, examination revealed complete resolution of
all lesions, with mild scarring on the vulva (Fig. 2). Conﬁrmatorye.
Fig. 1.Mutiple lesions noted on the vulva of a 45 years old, immunocompromised patient,
diagnosed with VIN3/CIS on biopsy.
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tive for dysplasia or carcinoma. She remains in remission after eleven
follow up months and has resumed normal sexual function since
then.Discussion
Throughout the last decade, incidence of VIN in United States for
women between ages 40–49 years has increased to a current rate of
2.9 per 100,000 women. This increase has been attributed to a num-
ber of factors, including changes in sexual behavior, smoking habits,
HPV infection, and increased surveillance (Joura et al., 2000). There
is a well-established association between high risk HPV genotypes
and VIN. HPV 16 and 18 are associated with 70–80% of VIN lesions,
and about 30–40% of invasive vulvar cancers (Hillemanns et al.,
2006).
VIN1 is typically a self-limiting infection that does not require treat-
ment. Conversely, higher grade lesions may require aggressive surgical
management to prevent progression to invasive cancer. In womenwith
multifocal and extensive disease, laser ablation is an alternative to exci-
sional therapy, provided there is no coexistent invasive cancer.
Although surgical treatment provides tissue sampling to evaluate
for invasive cancer, medical management achieves preservation of
vulvar anatomy and function, particularly in younger women. Inva-
sive disease must be excluded with colposcopy and biopsies prior to
initiating medical treatment. It is also recommended to preventFig. 2. Healthy vulva, with resolution of all lesions after treatment with Sinecatechins
ointment.extensive excisional and reconstructive surgery in women that are not
good candidates for surgery due to coexisting medical comorbidities
or extensive, multifocal vulvar lesions.
Medical options that include Imiquimod 5% applied three times
weekly to affected areas for 12–20 weeks is an effective therapy for
high grade VIN (Hillemanns et al., 2006). Side effects related to its use in-
clude erythema, erosions, andmoderate vulvar pain. Imiquimod is a top-
ical immune response modiﬁer that acts by stimulating local cytokine
production and cell mediated immunity, and thus has decreased effec-
tiveness in immunocompromised patients. Other available options for
conservative treatment include 5-Fluorouracil, topical 5-aminolevulinic
acid based photodynamic therapy, and Cidofovir (antiviral agent)
(ACOG, 2011).
Our patient had extensive multifocal disease involving her clitoris
that would require extensive surgical excision and reconstruction,
repeated biopsies showed absence of invasive cancer, and it failed
treatment with Imiquimod 5%. It, thus, presented a few therapeutic
dilemmas.
The failure of response to Imiquimod in our patient can be attrib-
uted to her low T cell count. We prescribed Sinecatechins as an alter-
native to surgical treatment and followed her closely to monitor side
effects, response, and signs of recurrence.
Sinecatechins, or polyphenol E compound, is a deﬁned green tea ex-
tract, availablewith trade nameVeregen® (Sinecatechin 15% ointment)
and is known to possess immunostimulatory, antiviral, antitumor and
antiproliferative properties (Stockﬂeth et al., 2008). It has a well-
established role in complete clearance of anogenital warts when used
three times daily for up to 16 weeks. Three randomized, double blinded,
placebo controlled trials have been published that prove the efﬁcacy,
safety and tolerability of Sinecatechins in treatment of genital and
perianal warts (Stockﬂeth et al., 2008; Gross et al., 2007; Tatti et al.,
2008). When compared to other patient applied drugs like Imiquimod
5% and 5-Fluorouracil, Sinecatechins was found superior in terms of
clearance rates, cost, less recurrence rates and less patient discomfort
(Tatti et al., 2008). Minor local reactions like erythema, burning pain,
pruritus were noted in 10–20% of patients. These patients continued
treatment due to noticeable improvement with use. The exact mecha-
nism of action of Sinecatechins in wart regression is yet to be identiﬁed,
but it has been shown to inhibit a broad range of enzymes and kinases
involved in the generation of inﬂammatory mediators. Its wide array
of biological activities shows great therapeutic potential in treatment
of other HPV related tumors (Tyring, 2012).
To our knowledge, this is the ﬁrst report of successful treatment of
VIN/CIS with Sinecatechins 15%. Prospective studies are warranted to
investigate its role in the treatment of VIN or other pelvic dysplastic
diseases.
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